STUTTGART, Germany I April 4, 2018 I 2018 was another record year for global sales of branded recombinant therapeutic antibodies and proteins: US$ 202 mln (+7.3% vs previous year). Major contributing factor to the growth were sales of therapeutic antibodies which showed a continuous annual growth rate (CAGR) of 14.1%...
TCR Engineered T-Cells are coming out of the shadows and into the light
The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cuttingedge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but...
All time high of biologics sales in 2017 driven by cancer and innovative anti-inflammatory antibodies
STUTTGART, Germany I March 12, 2018 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year 2017 reached an all time high of more than US$ 188 bln, as reported by La Merie Publishing. The increase by 11.9% compared with the previous year was driven by...
Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-penetrating biologics
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...
mRNA Vaccines & Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?
STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo and its immunogenicity. But two of the main problems of...
Oncolytic Viruses: a still undervalued technology with strong growth perspectives
STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment. The approval of...
Beyond anti-CD19 CAR T-Cells: the future of CAR T-cells depends on the convergence of technologies
STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a head-to-head race to be first on the market with anti-CD19...
Strong emergence of T-cell redirecting bispecific antibodies in clinical proof-of-concept studies
STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell...